𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL

✍ Scribed by Hohloch, Karin; Zwick, Carsten; Ziepert, Marita; Hasenclever, Dirk; Kaiser, Ulrich; Engert, Andreas; Höffkes, Heinz-Gert; Kroschinsky, Frank; Mesters, Rolf; Feller, Andreas C; Löffler, Markus; Trümper, Lorenz; Pfreundschuh, Michael


Book ID
121573770
Publisher
Springer
Year
2014
Tongue
English
Weight
300 KB
Volume
3
Category
Article
ISSN
2193-1801

No coin nor oath required. For personal study only.